| Ytd | -9.68% | |
| 1y | 107.41% |
| Open | 28.26 | Prev Close | 28.26 | Low | 27.49 | High | 28.27 | Mkt Cap | 97.32M |
| Vol | 31.56K | Avg Vol | 21.61K | EPS | -22.92 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 26.48 | 200-d Avg | 26.51 | 1yr Est | 0.00 |
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a b